Cost-effectiveness of daratumumab plus lenalidomide plus dexamethasone versus lenalidomide plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy

An analysis of the Pollux trial

Maiese, E. M., Graham, CN., Hawe, E., Le Moine, J-G., Abraham, I., & Senbetta, M. (2017). Cost-effectiveness of daratumumab plus lenalidomide plus dexamethasone versus lenalidomide plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: An analysis of the Pollux trial. Blood, 130.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Article

Long-term effects of a diet supplement containing Cannabis sativa oil and Boswellia serrata in dogs with osteoarthritis following physiotherapy treatments
Article

Community overdose surveillance
Article

Tailoring off the shelf global evidence with local implementation research can boost action on overweight and obesity